NOX-E36: Preliminary Phase I data

Preliminary data from a double-blind, placebo-controlled, single ascending-dose, U.K. Phase I trial in 72 healthy volunteers showed that all doses of IV and subcutaneous NOX-E36 were well tolerated. ...